Ascent Wealth Partners’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$234K Buy
2,926
+18
+0.6% +$1.48K 0.03% 172
2025
Q4
$248K Sell
2,908
-345
-11% -$28.3K 0.03% 167
2025
Q3
$253K Sell
3,253
-100
-3% -$7.81K 0.03% 161
2025
Q2
$262K Sell
3,353
-834
-20% -$62.2K 0.03% 156
2025
Q1
$303K Buy
4,187
+641
+18% +$45.9K 0.04% 152
2024
Q4
$263K Buy
+3,546
New +$248K 0.04% 154
2024
Q3
Sell
-3,531
Closed -$326K 160
2024
Q2
$326K Sell
3,531
-113
-3% -$10K 0.05% 136
2024
Q1
$348K Hold
3,644
0.05% 143
2023
Q4
$278K Sell
3,644
-105
-3% -$7.31K 0.05% 147
2023
Q3
$260K Buy
3,749
+109
+3% +$8.76K 0.05% 147
2023
Q2
$343K Buy
3,640
+632
+21% +$54.9K 0.06% 135
2023
Q1
$249K Sell
3,008
-24
-0.8% -$1.89K 0.05% 140
2022
Q4
$226K Sell
3,032
-278
-8% -$21.4K 0.05% 137
2022
Q3
$274K Buy
+3,310
New +$318K 0.07% 125
2022
Q2
Sell
-3,160
Closed -$372K 143
2022
Q1
$372K Sell
3,160
-90
-3% -$10.1K 0.07% 120
2021
Q4
$421K Sell
3,250
-132
-4% -$15.4K 0.08% 119
2021
Q3
$383K Sell
3,382
-1
-0% -$114 0.07% 128
2021
Q2
$350K Buy
3,383
+211
+7% +$19.9K 0.07% 128
2021
Q1
$265K Buy
3,172
+73
+2% +$6.17K 0.06% 111
2020
Q4
$283K Buy
3,099
+328
+12% +$27.2K 0.06% 105
2020
Q3
$221K Buy
+2,771
New +$216K 0.06% 103
2020
Q1
Sell
-3,228
Closed -$251K 117
2019
Q4
$251K Buy
3,228
+57
+2% +$4.45K 0.07% 107
2019
Q3
$232K Buy
+3,171
New +$223K 0.07% 109
2019
Q2
Sell
-3,150
Closed -$201K 128
2019
Q1
$201K Buy
+3,150
New +$180K 0.07% 117

Other funds holding EW

Ascent Wealth Partners's EW Position: Q1 2026 in Review

Ascent Wealth Partners increased its Edwards Lifesciences (EW) stake by 0.62% in Q1 2026, buying an estimated $1.48K and bringing the position to 2,926 shares worth $234K. The position accounts for 0.03% of the portfolio, ranked #172.

Ascent Wealth Partners first reported a position in EW in Q1 2019 and has held it in 24 quarters since. The position peaked at $421K in Q4 2021. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Ascent Wealth Partners held 2,926 shares of Edwards Lifesciences worth $234K as of Q1 2026.
  • Ascent Wealth Partners bought 18 Edwards Lifesciences shares in Q1 2026, an estimated $1.48K.
  • Edwards Lifesciences made up 0.03% of Ascent Wealth Partners's portfolio in Q1 2026, its #172 holding.
  • Ascent Wealth Partners first reported a position in Edwards Lifesciences in Q1 2019 and has held it in 24 quarters since.
  • Ascent Wealth Partners's Edwards Lifesciences position peaked at $421K in Q4 2021.
  • 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Ascent Wealth Partners's 13F filing for Q1 2026, filed 6 May 2026.